A Study of ES014 in Patients With Locally Advanced or Metastatic Solid Tumours

Summary

The purpose of this first-in-human, open-label, multicenter, non-randomized study designed to determine the maximum tolerated dose (MTD)/maximum administered dose (MAD), optimal biological dose (OBD), and recommended phase 2 dose (RP2D) of ES014 by evaluating the safety, tolerability, PK, pharmacodynamics, and preliminary clinical activity of ES014 administered intravenously to subjects with advanced solid tumors.

Timeline

Start

2023-02-24

Primary completion

2027-02-28

Completion

2027-02-28

Drugs

Indications